09.29.25 -- Buckle Up. It's A Strategic Drive To Successful Sourcing

Discover available CDMO capacity for critical fill/finish services, including sterile filling, lyophilization, and advanced packaging, at the Fill/Finish session of the Outsourced Pharma Capacity Update (Oct. 10). This virtual event highlights technologies and quality standards essential for safe, effective biopharmaceutical delivery. Engage in short, interactive presentations and connect with CDMOs ready to support your manufacturing needs. Open to biopharma companies, consultants, and investors seeking trusted partners for late-stage production. Save your spot today!

Review details on the FDA expedited review programs, the incentives for obtaining such designations, and the required information/data to better position your investigational product for success.

Liposome technology is an effective drug delivery tool but still presents difficulties. Learn how developers are meeting these challenges and the opportunities for advancement to maximize liposome usefulness.

Discover how combining experimental design with machine learning can streamline glycosylation profiling and accelerate the development of reliable analytical methods for therapeutic biologics.

Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers, identifying CDMOs that might be impacted by key events affecting their clients.

Explore strategies for effective supply chain management and overcoming modern supply chain challenges in the pharmaceutical industry.

Single-use technologies (SUTs) bring speed and flexibility to modern biomanufacturing, but realizing their full value requires robust, stage-specific risk management.

Did you know that a CDMO with extensive experience in protein variant characterization, CQA analytics, and patient-centric product development can ensure the safety and efficacy of your biotherapeutic?

This unique model to predict injection force is designed to decorrelate factors linked to formulation development and the ones linked to container and delivery device selection.

Combining rigorous target validation, early toxicity and pharmacokinetic (PK) testing, and an iterative design process is crucial for identifying viable drug candidates early.

Quality data for informed decision-making is well supported by a built-in network of lab digitization solutions and a commitment to the principles of data integrity.

This standardized yet flexible modular biomanufacturing system is designed to accelerate timelines, improve scalability, and enhance quality while reducing costs and environmental impact.

With cutting-edge innovations like smart glasses for live process insights and a data-sharing portal, we're able to provide the capacity and expertise to bring biologics to commercial success.

Whether scaling manufacturing capabilities, condensing supply, accelerating availability, or reducing the risk of a shortage, a manufacturing platform can be the difference between success and failure.

Our collaboration with MilliporeSigma encompasses every stage, including bioconjugation, linker and payload supplies, formulation development, and final fill/finish of drug substance.